Bisantrene

A cancer drug that is related to the anthracyclines, the most widely used class of chemotherapy drugs.

A cancer drug that is related to the anthracyclines, the most widely used class of chemotherapy drugs.

What is Bisantrene?

Bisantrene is a cancer drug that is related to the anthracyclines, the most widely used class of chemotherapy drugs.

Bisantrene is a cancer chemotherapy drug that has shown excellent activity in several cancers, notably Acute Myeloid Leukaemia (AML)

Bisantrene is a small molecule cancer drug related to the ‘anthracyclines’, the most widely used class of cancer chemotherapy drugs. However, unlike the anthracyclines, Bisantrene has a greatly reduced risk of cardiotoxicity (heart damage).

A comprehensive review of the science around Bisantrene was recently published in the International Journal of Cancer Research & Therapy.

This means Bisantrene may be used with patients who have reached their cardiotoxic limit with anthracyclines, or cannot tolerate anthracyclines due to existing heart conditions, age or other factors.

Bisantrene was tested in more than 40 phase II clinical trials during the 1980s and 1990s, before it was lost in a series of pharmaceutical mergers.

Before it was lost, Bisantrene demonstrated impressive activity in treating AML, so much so that it was approved for the treatment of AML in France in 1988.

“Bisantrene has been shown to have greatly reduced cardiotoxicity compared to anthracyclines and to be effective against some cancers that have relapsed after the patients have already received high levels of anthracyclines. This makes Bisantrene potentially well-suited as a second or third line treatment for patients who have reached their cardiotoxic limit of anthracyclines or whose cancer has become resistant to anthracycline treatment.”

– Race Oncology CSO Dr Daniel Tillett

History

2020

Phase II Bisantrene AML trial results released showing a 40% clinical response rate in a very hard to treat, late stage, patient population. Bisantrene identified as a potent inhibitor of FTO, a key marker in cancer development and growth.

2019

Race Oncology announces updated commercialisation strategy (“5-Paths”) around treating AML, breast and ovarian cancers.

2016

Race Oncology lists on the ASX (RAC) with the mission to rescue Bisantrene and return it to the clinic via the Named Patient Program in Europe.

2011-2015

Bisantrene rediscovered, new patents filed and orphan drug designation obtained by Update Pharmaceuticals.

1990s

Bisantrene was approved for marketing in France for the treatment of AML. French registration withdrawn after American Cyanamid was acquired by American Home Products.

1980s

Tested in more than 40 Phase II clinical trials to assess its efficacy and safety in a wide range of cancers. The studies covered nearly 2,000 patients and revealed Bisantrene to possess low cardiotoxicity and useful therapeutic efficacy in several cancers, notably AML, breast and ovarian.

1970s

Bisantrene discovered in the United States by US Pharmaceutical company Lederle (a division of American Cyanamid).